Axonics initiated with an Overweight at KeyBanc

KeyBanc initiated coverage of Axonics with an Overweight rating and $70 price target. The analyst believes Axonics is well positioned to continue driving “rapid penetration of its portfolio in a large underserved market.” The firm sees opportunity for an improvement in investor sentiment as some near-tension points around new competition and an ongoing intellectual property lawsuit are addressed.